Author: acn

HO CHI MINH CITY, VIETNAM, Apr 1, 2025 - (ACN Newswire via SeaPRwire.com) - analytica Vietnam 2025, Vietnam’s premier international trade fair for laboratory technology, analysis, biotechnology, and diagnostics, will officially open tomorrow at the Saigon Exhibition and Convention Center (SECC). Running from 2-4 April 2025, this highly anticipated exhibition promises to showcase groundbreaking innovations, cutting-edge technologies, and a dynamic conference program, bringing together over 300 exhibitors from 18 countries.Endorsed by the Ministry of Science and Technology in Vietnam and supported by the National Agency for Science and Technology Information and Statistics (NASTIS), the Center for Science and Technology Information (CESTI), the Key Laboratory of Analytical Technology for Environmental Quality and Food Safety Control (KLATEFOS), VNU, the Federal Ministry for Economic Affairs and Climate Action of Germany, and the Association of Small & Medium Enterprises (Singapore), analytica Vietnam continues to grow as the most influential laboratory event in Southeast Asia.In response to growing demand and expanding participation, analytica Vietnam introduces Hall A2 for the first time this year, adding 7,000 sqm of exhibition space in total, alongside the existing Hall A1. This expansion accommodates more exhibitors and innovations, reinforcing the event’s status as Southeast Asia’s leading laboratory exhibition.A Platform for Global Collaboration in the Laboratory Sector“The expansion with the new exhibition hall reflects our ongoing commitment to supporting the growth of the laboratory industry and fostering international collaboration,” said Mr. Michael Wilton, CEO of MMI Asia. “As Vietnam continues to emerge as a global hub for scientific and technological advancements, analytica Vietnam serves as a pivotal gateway for international companies seeking to enter this rapidly growing market, while providing local businesses access to world-class innovations.”This year, analytica Vietnam 2025 will feature an impressive lineup of exhibitors, including global leaders in laboratory technology, biotechnology, and analysis. The German Pavilion, Singapore Pavilion, and China Pavilion will be the largest ever at the event, underscoring the growing international interest in the Vietnamese and Southeast Asian laboratory markets. Additionally, delegations from Vietnam, Laos, Cambodia, Thailand, and Malaysia highlight the exhibition’s expanding international reach and its role as a key facilitator of cross-border partnerships.Pre-Show Press ConferenceBefore the official exhibition opening, a press conference was held on 31 March 2025 at the Crystal Palace Hotel, Ho Chi Minh City, where key industry players and media representatives gathered to discuss the significance of analytica Vietnam 2025.Key speakers included:- Mr. Vu Anh Tuan, Deputy Director, National Agency for Science and Technology Information and Statistics (NASTIS), who delivered the opening remarks, underscoring the event’s role in fostering technological innovation and international collaboration.- Mr. Michael Wilton, CEO of MMI Asia, who provided insights into analytica Vietnam’s evolution, emphasizing its expanding international reach and growing influence within the industry.- Representatives from leading exhibitors including ITS Vietnam, Waters, Kimteco Co., Ltd., and Hoa Viet Co., Ltd., who shared their experiences as returning participants, highlighting the strategic benefits of engaging with analytica Vietnam.Complementing the pre-show activities, analytica Vietnam 2025 organized exclusive Lab Tours on 31 March and 1 April 2025, granting the exhibitors behind-the-scenes access to some of Ho Chi Minh City’s most advanced laboratory facilities. These tours provided a unique opportunity to observe state-of-the-art research, laboratory operations, and cutting-edge technological applications in real-world settings.analytica Vietnam 2025 will feature a host of exciting new additions designed to engage attendees and provide valuable insights into the latest trends and innovations in the laboratory sector:- LIVE LAB: A first for Southeast Asia, the LIVE LAB is a fully operational laboratory integrated into the exhibition floor. Visitors will have the opportunity to witness live demonstrations of laboratory processes, interact with experts, and explore real-world applications of the latest technologies.- Startup Pavilion: Featuring emerging companies in the laboratory space, the Startup Pavilion will highlight new technologies and innovations shaping the future of the sector.- Lab Design and Construction Forum: This forum will delve into sustainable and efficient laboratory infrastructure, offering insights from industry leaders on the future of lab design.- Innovation Zone: A dedicated space showcasing breakthrough technologies transforming laboratory operations and industry practices.- Exclusive Lab Tours: Specially curated behind-the-scenes tours of leading research and testing facilities in Vietnam will offer participants a deeper understanding of local industry advancements.Additionally, the Academic Conference Program, one of the most anticipated segments of analytica Vietnam, will once again feature renowned thought leaders discussing critical industry trends, regulatory developments, and emerging research. Its strong reputation as a knowledge-sharing platform continues to attract top experts and professionals from around the world.Join the Industry’s Most Influential GatheringWith only one day left until the grand opening, excitement is building for analytica Vietnam 2025. The exhibition is set to provide an unparalleled platform for industry professionals, researchers, and business leaders to explore the latest innovations, exchange knowledge, and establish meaningful collaborations.Register now to be part of Vietnam’s premier laboratory technology event. For more details, visit www.analyticavietnam.comAbout analytica Vietnamanalytica Vietnam is the premier trade fair for laboratory technology, analysis, and biotechnology in Southeast Asia. Organized by Messe München, the event brings together industry professionals, researchers, and policymakers to showcase the latest technologies,exchange knowledge, and foster business collaborations. analytica Vietnam features an exhibition, conference, pre-event laboratory tours, buyer-seller programs, and networking opportunities, providing a comprehensive platform for the laboratory and biotechnology industries in the region. The upcoming edition is set to take place from April 2 to 4, 2025 at the SECC – Saigon Exhibition and Convention Center. More details can be found at https://www.analyticavietnam.com/.About analytica worldwideMesse München is the world’s leading trade fair organizer for laboratory technology, analysis and biotechnology. The international network of exhibitions includes analytica, analytica China, analytica Anacon India & India Lab Expo, analytica Vietnam and analytica Lab Africa. Additional information about these exhibitions and their programs of events is available at.About MMI Asia Pte LtdEstablished in 1992, MMI Asia is the wholly owned subsidiary and the regional headquarters of Messe München GMBH (MMG) and is one of the world largest and leading exhibition organizers. MMI Asia’s portfolio of events include editions of worldleading trade fairs from Munich – transport logistic & air cargo, analytica, ceramitec; as well as industry-specific events such as Glasstech and Fenestration Asia, Asia Climate Forum, and Singapore International Water Week. MMI Asia also provides consultancy in professional trade fair and conference management to government bodies, international trade and promotion organizations, and trade associations. For more information, please visit www.mmiasia.comAbout Messe MünchenAs one of the world’s leading trade fair organizers, Messe München presents the world of tomorrow at its about 90 trade fairs worldwide. These include twelve of the world’s leading trade fairs such as bauma, BAU, IFAT, electronica, and ISPO. Messe München’s portfolio comprises trade fairs for capital and consumer goods, as well as for new technologies. Together with its subsidiaries, it organizes trade fairs in China, India, Brazil, South Africa, Turkey, Singapore, Vietnam, Hong Kong, Thailand, and the U.S. With a network of more than 15 affiliated companies and almost 70 representations worldwide, Messe München is active in more than 130 countries. The more than 150 events held annually attract around 50,000 exhibitors and around three million visitors in Germany and abroad.Exhibition Contact:MMI Asia Pte. Ltd.Daniel ShiExhibition Directordaniel@mmiasia.com.sgPress Contact:MMI Asia Pte. Ltd.Joey NgMarketing Executivejoey@mmiasia.com.sg Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年4月9日 - (亚太商讯 via SeaPRwire.com) - 中国抗体制药有限公司（"中国抗体"或"本公司"；股份代号：3681）宣布，其SM17针对中重度特应性皮炎（AD）的创新疗法已完成1b期临床研究，并获得突破性顶线数据结果。SM17是一种靶向IL-25（IL-17E）受体通路的新型研究性生物制剂，其独特机制是通过结合IL-25（一种关键警报素）的共受体以阻断下游信号传导，从而抑制IL-25触发的炎症级联反应。SM17的竞争优势：- 首个兼具双重疗效达标的AD生物制剂 - 与已上市产品相比，这是首个也是目前唯一一个治疗期终点实现NRS-41应答率和EASI-752应答率都超过60%3治疗AD的生物制剂。- 较抗IL-4/13药物起效更快、止痒更深4 --- SM17止痒效果最早第2周显现（已上市药物通常为4~6周），SM17治疗结束时NRS-4应答率超过90%（已上市药物通常为30~40%）。- 较JAK抑制剂更安全5 --- 未报告严重不良事件（SAE）或≥3级药物相关不良事件（TRAE），严重感染及主要不良心血管事件（MACE）风险极低。1 NRS-4：瘙痒峰值数值评价指标（PP-NRS）周平均值自基线改善≥4分2 EASI-75：湿疹面积与严重程度指数（EASI）改善≥75%3 SM171b期实际应答率，NRS-4:91.7%，EASI-75:75.0%4 度普利尤单抗注射液（达必妥）说明书,SOLO-1 & SOLO-2临床试验5 乌帕替尼缓释片（瑞福）说明书,Measure Up 1 & Measure Up 2临床试验本次1b期研究评估了SM17两种剂量（200mg与600mg）在中重度AD患者中的安全性及疗效。结果显示，SM17耐受性良好，未出现SAE或≥3级TRAE。有效性方面，SM17治疗组在瘙痒缓解、皮损修复及患者生活品质等次要终点上全面优于安慰剂组。研究采用16周随机、双盲、安慰剂对照设计，纳入32例中重度AD成人患者（多数曾对外用皮质激素治疗应答不足），也纳入了曾接受生物制剂（杜普利尤单抗）或JAK抑制剂（乌帕替尼）治疗的患者。至第12周时，高剂量组75.0%（9/12）患者的湿疹面积及严重程度指数（EASI）较基线改善≥75%（EASI-75），而安慰剂组应答率为0.0%，两组应答率差异达75.0%（95%CI：32.00~91.11）。低剂量组50.0%（6/12）患者达到EASI-75标准，较安慰剂组应答率差异为50.0%（95%CI：9.27~74.62）。在高剂量组中，41.7%（5/12）患者第12周时达到研究者整体评估量表（vIGA-AD™）0分（完全清除）或1分（几乎清除）且较基线改善≥2分（vIGA-AD 0/1），较安慰剂组差异为41.7%（95%CI：2.28~68.05）。低剂量组该项应答率为25.0%（3/12），差异为25.0%（95%CI：-11.22~53.23）。尤为突出的是，高剂量组有91.7%（11/12）的患者于第12周时达到瘙痒峰值数字评分量表（PP-NRS）周平均值较基线改善≥4分（NRS-4），而安慰剂组该项指标无应答患者。即便在低剂量组，也有66.7%（8/12）患者的实现该终点应答，与安慰剂组形成鲜明对比。在起效时间方面，无论高剂量组或低剂量组，SM17均在给药后第2周时即显现显著止痒效果。随着治疗推进，至第12周时，高、低剂量组PP-NRS评分较基线平均降低幅度分别达68%和57%，显著优于安慰剂组（18%）。两个治疗组的止痒效果持续维持至第16周，即末次给药（第10周）后6周。皮肤损伤修复改善趋势和止痒效果类似，两个治疗组第12周EASI评分较基线平均降幅分别为73%（高剂量组）和57%（低剂量组），而安慰剂组平均降幅为42%。此外，本次1b期研究还达成了EASI50和EASI90的12周评估终点，并在SCORAD评分、AD体表面积（BSA）以及患者生活品质问卷（DLQI）等其他皮肤修复指标上均明显优于安慰剂组。主要疗效终点结果汇总如下表所示：终点SM17高剂量（N=12）SM17 低剂量（N=12）安慰剂（N=8）EASI 50（%）第12周83.366.725.0第16周91.758.325.0EASI 75 (%)第12周75.0500.0第16周41.741.70.0EASI 90 (%)第12周41.716.70.0第16周41.741.70.0IGA 0/1 (%)第12周41.725.00.0第16周33.341.70.0NRS-4（%）第12周91.766.70.0第16周75.058.325.0本次研究的安全性研究结果，与SM17在美国1期和中国1a期桥接研究中观察到的安全性特征总体一致。在SM17治疗组中，最常见的治疗引致不良事件（TEAEs，发生率≥10%）为鼻咽炎和尿路感染，治疗组合并发生率与安慰剂组发生率的差异小于5%。中国抗体主席、执行董事兼首席执行官梁瑞安博士表示："SM17有望成为特应性皮炎（AD）领域的全球首创且同类最优疗法。该市场单个革命性药物即可实现数十亿美元年收入。对于大多数中重度AD患者而言，瘙痒是最关注的临床症状，而由瘙痒引发的搔抓行为很可能是导致AD慢性炎症反复发作的关键驱动因素。SM17不仅具备优异的安全性特征，其皮损清除效果与现有最优疗法相当，更在患者最迫切的未满足临床需求 --- 快速缓解瘙痒方面展现卓越疗效。通过填补当前治疗方案的这些关键空白，SM17有望重新定义这一顽固性疾病的治疗标准。我们正加速临床开发并积极寻求合作，以拓展其全球影响力。下一步我们将启动中重度AD成人患者的2期试验。此外，临床前研究还显示SM17对哮喘、慢性鼻窦炎伴鼻息肉（CRSwNP）及特发性肺纤维化（IPF）等Th2驱动疾病具有治疗潜力，在AD治疗以外具备广阔的首创且最优疗法的应用前景。"关于特应性皮炎市场特应性皮炎（AD）是一种慢性炎症性皮肤疾病，其发病机制复杂，涉及遗传易感性、皮肤屏障功能障碍、免疫系统失调及环境因素等多重作用。该疾病的免疫学特征以Th2型免疫反应为主导，涉及胸腺基质淋巴细胞生成素（TSLP）、白细胞介素（IL-4、IL-13、IL-5、IL-33、IL-31）、OX40及JAK/STAT信号通路等多种介质。AD通常在婴儿期发病，约50%患者在1岁前出现症状，病程呈慢性反复发作特征。流行病学研究显示，全球AD患者至少为2.3亿人。中国患者规模尤为庞大，超过7000万人，其中中重度病例占比约28%。相比之下，美国成人AD患者约1650万人，中重度病例占比约40%。根据Precedence Research资料，2023年全球AD药物市场规模为136.2亿美元，预计到2034年将增长至314.4亿美元。现有治疗手段包括局部用药（如糖皮质激素[TCS]、钙调磷酸酶抑制剂[TCI]）、口服抗组胺药和生物制剂等，其疗效各异且各具优缺点。其中外用糖皮质激素（TCS）、外用钙调磷酸酶抑制剂（TCI）、口服抗组胺药物等治疗仍是目前治疗特应性皮炎的常用方法，而度普利尤单抗（Dupilumab）等现有疗法已显著改善患者生活，但其局限性（如起效慢、止痒效果不足、长期使用安全性问题）仍令大量患者需求未被满足。另一款药物JAK抑制剂乌帕替尼则存在用药安全性的问题。2024年，度普利尤单抗全球销售额突破140亿美元，印证AD市场的巨大潜力，也推动药企加速开发差异化疗法。当前，AD赛道竞争焦点主要集中于靶点创新：中国和全球AD临床在研TOP10靶点中有7个靶点重合，且前2大靶点均为IL-4Rα和JAK1；从临床分期来看，中国处于3期及以后临床阶段的占比仅约14%，低于全球的23%（不含2/3期），说明国内仍以Fast-Follow为主；国内靶点集中度更高，TOP3靶点（IL-4Rα、JAK1和PDE4）临床数量占比高达46%，相比之下，全球AD临床靶点分布更为均衡。关于SM17SM17是全球首创（First-in-Class）的人源化IgG4-κ单克隆抗体，也是首个靶向IL-25受体的同类药物，具有治疗特应性皮炎（AD）、哮喘、特发性肺纤维化及其他免疫疾病的潜力。SM17通过结合2型固有淋巴细胞（ILC2s）和辅助性T细胞（Th2）表面的IL-25受体（又称IL-17RB），阻断IL-25诱导的级联反应，抑制下游Th2细胞因数（如IL-4、IL-9和IL-13）的释放。IL-25是一种被归类为「警报素」的关键细胞因数，研究证实其与自身免疫性及炎症性皮肤病的发病机制密切相关，尤其在AD中作用显著。目前获批的AD疗法（包括生物制剂）虽能显著改善湿疹面积与严重程度指数（EASI）及患者生活品质，但仍存在起效缓慢（尤其是止痒效果）或安全性问题。凭借其创新作用机制，SM17有望成为AD治疗的新选择，甚至更优方案 - 其止痒起效迅速、皮损修复效果显著且安全性良好，可解决当前疗法未满足的临床需求。靶向受体（IL-25R）与靶向配体（IL-25）的差异以AD为例，受刺激的皮肤会持续释放IL-25，而直接中和IL-25的抗体疗法无法快速缓解症状。SM17的独特之处在于以非竞争性方式阻断IL-25受体亚基（IL-17RB）。我们的内部资料表明，SM17在不影响IL-25与受体结合的情况下阻断信号传导，从而快速抑制由IL-25和IL-25受体相互作用引发的瘙痒和炎症反应。此外，细胞表面受体数量有限。当SM17完全占据这些受体后，无论IL-25释放量多少，信号传导均被终止。这一机制使得SM17能实现快速、持久的抑制效果，且无需高剂量给药。相比之下，靶向IL-25的抗体需直接中和配体。由于AD患者皮肤持续释放IL-25，此类疗法必须使用高剂量以「清除」新释放的IL-25，导致瘙痒和炎症缓解延迟。关于中国抗体制药有限公司中国抗体制药有限公司聚焦研究、开发、生产及商业化免疫性疾病疗法。中国抗体的总部位于香港，研发基地位于香港，生产基地位于中国。公司注重科技研发，其旗舰产品舒西利单抗（Suciraslimab, SM03）为全球首项潜在用以治疗类风湿关节炎及其他免疫疾病的抗CD22单抗。舒西利单抗已在中国完成类风湿关节炎3 期临床试验，并正待中国国家药监局批准治疗类风湿关节炎的上市销售批准。此外，本公司还有多个全球首创在研药物，部分已处于临床阶段，适应症覆盖类风湿关节炎、干燥综合症、系统性红斑狼疮、特应性皮炎、特发性肺纤维化、哮喘等具有重大未满足临床需求的疾病。新闻垂询纵横财经公关顾问有限公司吴慧怡 电话：+852 2864 4831 冯静仪 电话：+852 2114 4939 雷远睿 电话：+852 2114 2881 程梓豪 电话：+852 2864 4894 电邮：sprg_sinomab@sprg.com.hk Copyright 2025 亚太商讯 via SeaPRwire.com.

圣地亚哥, 2025年4月9日 - (亚太商讯 via SeaPRwire.com) - 通用原子航空系统公司（GA-ASI）与韩国的韩华航天公司（Hanwha Aerospace）已达成协议，双方将在全球国防市场上合作开发和生产无人机系统（UAS）。此次合作是在2024年一项重大飞行演示成功完成后达成的。当时，两家公司从韩国海军的两栖登陆舰“独岛号” (ROKS Dokdo, LPH-6111) 上成功发射了一架 GA-ASI MQ-1C “灰鹰”® 短距起降（GE STOL）无人机，该舰正在韩国浦项外海航行中。该演示展示了 GE STOL 安全在多种具备飞行甲板的舰艇上运行的能力，为美军及其盟友提供了多域作战的新选择。此次成功也促成了 GA-ASI 与韩华签署新协议，共同投资并拓展新的无人机业务机会。“我们很高兴能与韩华进一步拓展并深化合作关系，” GA-ASI 首席执行官林登·布鲁（Linden Blue）表示，他曾亲自监督了2024年11月12日的海上飞行演示。“灰鹰 STOL 的试飞获得了韩国海军的积极评价，我们知道韩华已经准备好与 GA-ASI 共同投资，在韩国和美国发展无人机业务。”灰鹰 STOL（短距起降）是同类中唯一具备中空长航时性能、可在具备飞行甲板的战舰（如两栖舰和航母）上运行而无需弹射器或阻拦装置的无人机。它还可从简易跑道、公路、海滩、停车场等地起降，实现真正的跑道独立性。韩华航天计划投资超过3000亿韩元（约合2.035亿美元），用于 GE STOL 及其无人机发动机的开发与生产设施，扩大研发活动，并在韩国与 GA-ASI 美国工厂同时提供生产基础设施。这一举措是在 GA-ASI 过去及持续对 STOL 技术投入的基础上进一步加强的。韩华还计划通过招聘专业人才创造就业机会，挖掘国内零部件及材料合作伙伴，促进本土无人机产业生态的发展。GA-ASI 预计该合作将在未来十年内创造近1万个就业岗位，其中在美国将创造至少500个岗位。韩华航天副董事长金东官表示：“韩华航天将无人系统视为未来国防的战略支柱。通过与 GA-ASI 的合作，我们希望加强主权防卫能力，扩大韩国在全球无人机系统市场的影响力，并为韩美联盟的进一步巩固做出贡献。”曾被称为“莫哈维”的灰鹰短距起降无人机（Gray Eagle STOL），在大量采用现役并已成熟投产的“灰鹰25M”机体平台的基础上，提供了一种性能强大、成本更低、技术风险更小的新型飞机，相较于从零设计的方案更具可行性。灰鹰 STOL 创下了多项航空领域的首次纪录，包括从“独岛号”舰上起飞、在英国航母“威尔士亲王号”（HMS Prince of Wales, 09）上实现发射与回收、在亚利桑那州尤马试验场进行实弹测试等。该机型为各国军队提供了独特平台：具备全套功能的中空长航时无人机系统，不仅具备强大战场任务载荷能力，还能从舰艇、简易地面或其他高战备需求的地点进行短距起降。关于韩华航天韩华集团是韩国第七大企业集团，业务涵盖航空机电、清洁能源与海洋解决方案、金融以及零售和服务等多个领域。韩华航天在航空燃气涡轮发动机及其零部件、航空器组件、空间系统、导弹系统、陆军和海军武器系统等方面，具有世界领先的设计、开发、组装与维护能力，并在相关产品领域提供高度专业化的组织级与基地级维修支持服务。 官方网站：www.hanwha.com关于 GA-ASI通用原子航空系统公司（GA-ASI）是通用原子公司的子公司，致力于设计和制造成熟可靠的远程驾驶航空系统（RPA）、雷达及电光和相关任务系统，包括 Predator® RPA 系列和 Lynx® 多模式雷达。GA-ASI 运营超过 800 万飞行小时，提供具备长航时和任务能力的航空平台，并集成传感器和数据链系统，以实现持续态势感知。公司还研发多种传感器控制和图像分析软件，提供飞行员培训及支持服务，并开发超材料天线。更多信息，请访问： www.ga-asi.com 。Avenger、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 和 SkyGuardian 均为通用原子航空系统公司在美国及其他国家/地区注册的商标。联系信息GA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101来源: General Atomics Aeronautical Systems, Inc. Copyright 2025 亚太商讯 via SeaPRwire.com.

SINGAPORE, Apr 10, 2025 - (ACN Newswire via SeaPRwire.com) - How a small business presents and sells its offerings can be the difference between success and failure. GoDaddy has launched Show in Bio to help small businesses increase sales and stand out on social media.This affordable tool offers flexibility for small business owners not yet ready to build a website, enabling them to showcase their products or services on social media channels, including Instagram, TikTok, Facebook, X, Pinterest and LinkedIn, and interact with customers through channels like WhatsApp to close sales. Using artificial intelligence (AI) to quickly draft product information, such as name, description, and price, and create a personalized one-page sales catalogue in minutes, no technical skills are required to use the tool.Entrepreneurs who run their business on social media are more confident using AIResearch from GoDaddy’s 2025 Global Entrepreneurship Survey found over one in four (28%) of small business owners globally primarily run their business on social media. This shift in small business ownership to social-first entrepreneurs heightens the importance of how a small business sells online. GoDaddy’s research has found these social-first entrepreneurs are younger, more optimistic about business performance and more confident in their ability to leverage AI for their business. This trend reveals not only the growth potential of social-first businesses, but also how technology – specifically AI – is a key enabler to innovate, scale and thrive.Start a business on social media with low spend and without the need to build a websiteShow in Bio allows entrepreneurs to start a business quickly with low spend, even validating a business idea before launching it. While perfect for small business owners who may not have yet built a website, the tool also supports domain integration, allowing those with an established online presence to use their own domain for a seamless branded experience.Key features and benefits include:Centralize Your Links – Put all your important content in one shareable link.Drive Engagement – Drive traffic to key offers and updates instantly by sharing your link in bio on social channels.Showcase Products – Create a captivating catalogue with images and videos directly on your page.Domain Integration – Use your own domain for a seamless and branded experience.Save Time with AI – Generate quality product information and profile bios fast, no tech skills required.“We’re supporting entrepreneurs to start their online business wherever it makes the most sense for them – including on social media,” said Selina Bieber, Vice President of International Markets at GoDaddy. “The rise of social media in the last 20-plus years has captured a significant share of internet activity, but it hasn’t diminished the need for businesses to have their own brand and their own identity.“Show in Bio is an enhanced link in bio solution built to support small businesses run on social media, directly addressing challenges such as driving traffic, lack of technical skills and setting up a website while simplifying social selling.”About GoDaddy GoDaddy helps millions of entrepreneurs globally start and scale their businesses. People come to GoDaddy to name their idea, build a website and logo, sell their products and services, and accept payments. GoDaddy Airo®, the company’s AI-powered experience, makes growing a small business faster and easier by helping them to get their idea online in minutes, drive traffic and boost sales. GoDaddy’s expert guides are available 24/7 to provide assistance. To learn more about the company, visit www.GoDaddy.com.Issued on behalf of GoDaddy.For more information, contact:Fekra Communicationsinfo@fekracomms.com Copyright 2025 ACN Newswire via SeaPRwire.com.

佛罗里达州西棕榈滩, 2025年4月8日 - (亚太商讯 via SeaPRwire.com) - U.S. Polo Assn. 美国马球协会官方品牌(USPA）正式发布其标志性的2025年春夏运动风尚系列。本季系列以加州阳光明媚的圣地亚哥为背景，将品牌现代美式风格与美丽的海滩和公园景致完美融合。 U.S. Polo Assn.从拉荷亚迷人的海岸，到历史悠久的巴尔博亚公园，再到郁郁葱葱的Lakeside马球俱乐部，这些标志性地点共同构成了2025春夏系列的理想舞台。本季系列还特别推出令人期待的**135周年限量纪念系列**，以致敬品牌名称的由来及其灵感来源——美国马球协会（USPA）。 “U.S. Polo Assn.全球设计团队的每一季系列，既承载我们在马球运动中的深厚历史，也不断推动品牌创意的边界。”USPA Global（负责全球运营和市场推广、管理该数十亿美元品牌）的总裁兼首席执行官J. Michael Prince表示，“本季系列不仅体现了我们对经典风格的坚持，也展现了我们致力于打造富有运动灵感的服饰，传承品牌传奇，同时激发全球消费者与运动爱好者的热情。”U.S. Polo Assn. 2025春夏系列沿加州迷人海岸拍摄，整体设计以优雅而丰富的色彩为主，融合柔和的粉彩与亮丽的色调。模特与马球运动员共同演绎本季多种适合暖季的面料，如透气亚麻、柔软毛圈布和轻盈针织，完美适应季节交替的穿着需求。U.S. Polo Assn. 最新服饰中，色彩点缀与多样的质感面料相得益彰，展现于时尚马球衫、舒适牛仔系列及柔软应季连衣裙等单品之中。整个系列还大量运用了大胆多彩的条纹设计，并配以活力十足的配饰，如时尚鞋履、潮流太阳镜和别致斜挎包，打造出充满个性的春夏造型。“U.S. Polo Assn. 2025春夏系列注重风格与舒适并重，采用高品质材料与细致设计，便于消费者在季节转换之际轻松融入日常穿搭中。”U.S. Polo Assn. 商品与设计主管Jessica Ramesberger表示，“这一季的系列为全家人带来兼具趣味性、实用性与时尚感的穿搭选择。”此外，U.S. Polo Assn. 也自豪地宣布将在2025年春季推出**135周年纪念限量系列**，以庆祝品牌在马球运动中的深厚传承与荣耀历史。该特别系列精选服装与配饰，彰显品牌一贯的经典美式风格，并突出标志性的红、白、蓝三色条纹。“圣地亚哥悠闲的生活节奏，阳光沙滩的惬意氛围，完美契合了我们2025年春夏系列的精髓，尤其是这次推出的标志性135周年纪念系列。”USPA Global全球市场副总裁Stefanie Coroalles表示，“从阳光普照的拉荷亚海滩，到恒久魅力的巴尔博亚公园，再到活力四射的Lakeside马球俱乐部，我们特别选取的拍摄地突出了本季设计的运动感、趣味性与休闲风格。”Coroalles补充道：“这些独特场景不仅体现了加州轻松却富有冒险精神的生活方式，也完美契合我们品牌将时尚、舒适与可得性相结合的理念。”U.S. Polo Assn. 以其真实、运动启发的风格闻名于世，2025春夏系列延续品牌的经典美式风格，并保留了经久不衰的标志性单品。此外，本季系列中也包括了部分隶属于品牌全球可持续发展计划“USPA Life”的产品。该计划号召大众“Play Your Part”（积极参与），代表品牌在环境与社会责任方面的承诺，旨在通过对人、产品与地球的正向影响，支持可持续发展目标。该系列男装、女装与童装现已于全球U.S. Polo Assn. 门店及线上平台同步发售。关于 U.S. Polo Assn. 和 USPA GlobalU.S. Polo Assn. 是美国马球协会（USPA）的官方品牌，该协会成立于1890年，是北美最大的马球俱乐部及马球运动员联合会。U.S. Polo Assn. 拥有数十亿美元的全球影响力，并通过超过1,100家 U.S. Polo Assn. 零售店以及数千个其他分销点在全球190多个国家销售，为男性、女性和儿童提供服装、配饰和鞋类产品。与美国 ESPN 以及印度 Star Sports 达成的历史性协议现已转播由 U.S. Polo Assn. 赞助的多项世界顶级马球锦标赛，使这项激动人心的运动首次向全球数以百万计的体育迷开放。据 License Global 报道，U.S. Polo Assn. 一直被评为全球顶级体育授权商之一，与 NFL、NBA 和 MLB 齐名。此外，这一受体育启发的品牌因其全球及数字化增长而在国际上获得奖项认可。凭借其作为全球品牌取得的巨大成功，U.S. Polo Assn. 曾在《福布斯》、《财富》、《现代零售》和《GQ》以及 Yahoo Finance 和 Bloomberg 等众多知名媒体上亮相。欲了解更多信息，请访问 uspoloassnglobal.com 并关注 @uspoloassn。USPA Global 是 USPA 的子公司，管理着全球价值数十亿美元的 U.S. Polo Assn. 品牌。通过其子公司 Global Polo Entertainment (GPE)，USPA Global 还管理着提供体育和生活方式内容的 Global Polo TV。欲了解更多体育内容，请访问 globalpolo.com。联系信息Kaela DrakePR & Communications Specialistkdrake@uspagl.com+001.561.461.8596Stacey KovalskyVice President, Global PR and Communicationsskovalsky@uspagl.com+001.561.790.8036来源: U.S. Polo Assn. Copyright 2025 亚太商讯 via SeaPRwire.com.

香港, 2025年4月8日 - (亚太商讯 via SeaPRwire.com) - 当前，做好金融"五篇大文章"，服务国家重大战略和经济社会高质量发展，已成为金融行业的重要课题。政府工作报告提出，2025年我国要完善科技金融、绿色金融、普惠金融、养老金融、数字金融标准体系和基础制度。海通恒信（1905.HK）将自身发展融入国家大局，紧紧围绕金融"五篇大文章"，持续优化业务布局，打造一条高质量发展路径，经营质效持续提升。2024年，公司实现收入总额及其他收入、收益人民币88.55亿元，净利润人民币15.13亿元。截至2024年底，资产总额人民币1,112.97亿元，权益总额人民币199.83亿元。助力新质生产力发展 激发产业新动能新质生产力是经济高质量发展的重要驱动力，海通恒信深刻洞察这一趋势，在科技金融、绿色金融以及数字金融领域积极布局，服务新质生产力企业全生命周期资金需求，助力加快新质生产力发展和现代化产业体系建设。在科技金融领域，海通恒信顺应发展新趋势，加快在战略性新兴产业和未来产业的布局，积极探索智能制造产融合作新模式，作为唯一入选上海市智能制造产融生态联合体的融资租赁公司，并在商业航天和低空经济领域成功实现首单业务突破。2024年，海通恒信科技金融全年投放人民币48.57亿元，同比上升70.67%，其中专精特新业务投放人民币21.72亿元，同比上升91.18%，为众多处于关键发展阶段的科技企业提供了及时、有效的资金支持。在绿色金融领域，海通恒信作为首批入驻上海绿色金融服务平台的融资租赁机构，充分发挥自身专业优势，推动绿色租赁业务发展，成功落地首单工商业储能直租业务，为企业提供了更加灵活、高效的绿色融资解决方案。同时，参与编制《中国绿色租赁年度发展报告》，积极配合相关部门推动出台上海市绿色租赁业务认定的地方标准，为绿色金融的规范化发展贡献了重要力量。2024年末，公司绿色金融资产余额约人民币207亿元，生息资产余额占比22%，相较2023年同期约人民币203亿元的规模，不论是资产规模还是生息资产余额占比均有所提升。在数字金融领域，海通恒信深度布局算力及人工智能产业，2024年实现数字金融业务投放人民币超20亿元，其中算力租赁业务投放超人民币超5亿元。值得一提的是，公司持续加强与算力领域领军企业的战略合作，助力传统IDC向智算中心转型。截至2024年末，海通恒信数字金融资产余额约人民币50亿元，余额和占比均较去年末实现一定增长，为数字经济的产业发展提供了有力支持。践行金融为民 提升民生福祉金融的本质是服务人民，海通恒信在普惠金融和养老金融领域的积极探索，正是对这一理念的生动诠释。面对小微企业融资痛点，海通恒信持续优化普惠金融业务策略，加强普惠业务风险把控，优选具有经营优势及优质发展潜力的中小微企业予以支持。2024年全年，公司普惠金融业务投放人民币超74亿元，为超2,600家中小微企业提供了设备和资金支持，有效缓解了中小企业融资难、融资贵的问题。此外，公司还入选了上海普惠金融顾问制度试点金融机构，进一步提升了对中小企业的服务深度和广度，为实体经济的发展筑牢根基。随着人口老龄化进程加快，养老金融的重要性日益凸显。海通恒信重点关注优质医养结合机构和康养设备厂商的金融服务需求，开创性打造居家养老设备租赁产品，出台针对高端养老机构和普惠养老机构的产品方案，并成功实现首单项目投放。这些举措不仅满足了养老市场的多样化需求，也为养老产业的发展提供了创新的金融模式，推动了养老产业的升级和发展。通过深耕金融"五篇大文章"，海通恒信在为实体经济发展做出贡献的同时，也推动自身资产结构持续优化，进一步增强了内生发展动能。2024年，公司生息资产平均收益率为6.37%，加权平均净资产回报率为8.10%。未来，海通恒信将充分发挥"融资+融物"特性，围绕金融"五篇大文章"方向，加大业务投放，提升服务实体经济质效，推动融资租赁行业高质量发展。 Copyright 2025 亚太商讯 via SeaPRwire.com.

New York, New York--(ACN Newswire via SeaPRwire.com - April 7, 2025) - Spiking, a leader in AI-driven financial technology, is thrilled to participate in IBM Z Day: Special Edition, a landmark virtual conference hosted by IBM on Tuesday, April 8, 2025, from 10:00 AM to 5:00 PM Eastern Time (ET). This complimentary one-day event invites technology enthusiasts, industry leaders, and innovators worldwide to witness the next era of enterprise computing and artificial intelligence, spotlighting Spiking's TradeGPT as a transformative force in capital markets.Event HighlightsGroundbreaking Keynote Announcement: At 10:00 AM ET, a live broadcast from New York City will unveil a major advancement in enterprise technology, including a new AI chip that Spiking's TradeGPT will leverage for unparalleled performance.Specialized Technical Tracks: Attendees can explore three cutting-edge tracks:IBM zNext: Discover the latest IBM mainframe, boasting up to 8x on-chip AI processors per core, enabling TradeGPT's unmatched scale, speed, and security.AI & Data: Learn how Spiking integrates advanced AI into mission-critical financial workloads without additional infrastructure.App Dev & IT Ops: See how AI-driven automation boosts productivity and efficiency, a cornerstone of Spiking's development strategy.Curated Experiential Journeys: Customize your experience with three paths:Security: Explore post-quantum encryption, critical for safeguarding TradeGPT's real-time financial insights.New to Z: Gain foundational knowledge about IBM Z, powering Spiking's enterprise ambitions.Developer: Dive into technical sessions tailored for developers enhancing platforms like TradeGPT.Earn Digital Credentials: Participants can earn up to four prestigious IBM digital skills badges, enhancing professional expertise.Dr. Clemen Chiang, CEO of Spiking, stated, "IBM Z Day: Special Edition is a defining moment for enterprise innovation, and we're proud to be at its forefront. Our LLM-based TradeGPT will harness the new AI chip unveiled on April 8, 2025, delivering unmatched speed and intelligence for real-time capital market decisions. This, alongside other surprises, positions Spiking to reshape how businesses leverage AI." Chiang's vision reflects Spiking's leadership in driving AI-powered transformation.Adam LG Ring, Global Head of the IBM Z Startup Community and Spiking's advisor, added, "As Spiking scales to volumes rivaling OpenAI, moving to an enterprise-scale solution with world-class security is both logical and essential. The latest IBM Z offerings, unveiled April 8, 2025, are cost-effective at scale-perfect timing for TradeGPT to lead the capital markets." Ring's endorsement highlights the strategic alignment between Spiking's goals and IBM's technology.Through IBM Z Day: Special Edition, Spiking joins IBM to offer a dynamic platform for connecting with global thought leaders, uncovering industry-defining trends, and showcasing innovations in AI, hybrid cloud, and post-quantum security. Tailored for all skill levels, this event is a must-attend for finance and tech professionals alike.Registration & AgendaRegister Now: Reserve your spot at https://ibm.biz/specialzday1Full Agenda: Explore the complete lineup of sessions and speakers at http://ibm.biz/agendazdayse2025Join Spiking and IBM on April 8, 2025, for a day of innovation, education, and networking as we unveil the future of enterprise computing and AI in capital markets.Media ContactNicole YeeMedia RelationsEmail: info@spiking.comPhone: 1-570-SPIKINGNote: All times are in Eastern Time (ET). Please adjust for your local time zone.About SpikingSpiking is a trailblazer in AI-driven financial technology, empowering businesses and investors with real-time, intelligent solutions for capital markets. Through its flagship product, TradeGPT, Spiking leverages cutting-edge AI to deliver unmatched performance and insights.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247585 Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Apr 7, 2025 - (ACN Newswire via SeaPRwire.com) - TVS Motor Company (TVSM), a leading global manufacturer of two and three-wheelers, is set to strengthen its electric vehicle (EV) presence in Southeast Asia through the integration of ION Mobility’s assets, intellectual property, and talent into its operations. Southeast Asia represents one of the world’s fastest-growing regions for motorbike usage, offering a significant opportunity for expansion.TVSM has been a strategic investor in ION Mobility, a full-stack EV company known for its robust in-house capabilities across industrial and product design, mechanical and electrical engineering, embedded and power electronics, firmware, software, and supply chain solutions. This integration, combined with TVSM’s deep expertise in electric mobility, marks a major step toward unlocking new possibilities in the region.Commenting on the development, Sharad Mohan Mishra, President Group Strategy, TVS Motor Company, said: “We were an early strategic investor in ION Mobility, attracted by their focus on delivering smart, sustainable, and exciting mobility solutions for ASEAN markets. Our ‘Reimagine 2030’ vision strongly aligned with their mission. With the acquisition of ION Mobility’s assets, IP and core team, we are thrilled to bring their entrepreneurial energy, design thinking and engineering strength into TVSM. Combined with our R&D depth, quality systems, and manufacturing scale, this partnership positions us to accelerate market penetration and grow our share across Southeast Asia.”TVS Motor is already a formidable player in the global EV landscape, with nearly 600,000 customers choosing its flagship electric scooter, TVS iQube. The company has developed end-to-end in-house capabilities across EV components - battery systems, battery management, vehicle control units, and connected platforms - and holds more than 650 patents in the EV domain.Earlier this week, TVS Motor Company announced that its wholly owned subsidiary TVS Motor (Singapore) Pte Ltd acquired select assets from ION Mobility and also divested its stake in the company. Following this move, James Chan, Founder and CEO of ION Mobility, has joined TVS Motor Company as Senior Vice President. He will lead TVSM’s business across ASEAN while also spearheading the development and launch of the M1-S electric mobility platform. The M1-S is already generating strong interest in ASEAN markets for its striking design, impressive range, agile acceleration, and suitability for daily commutes.About TVS Motor CompanyTVS Motor Company (BSE:532343 and NSE: TVSMOTOR) is a reputed two and three-wheeler manufacturer globally, championing progress through sustainable mobility with four state-of-the-art manufacturing facilities located in India and Indonesia. Rooted in our 100-year legacy of trust, value, and passion for customers, it takes pride in making internationally accepted products of the highest quality through innovative and sustainable processes. TVS Motor is the only two-wheeler company to have won the prestigious Deming Prize. Our products lead in their respective categories in the J.D. Power IQS and APEAL surveys. We have been ranked No. 1 Company in the J.D. Power Customer Service Satisfaction Survey for four consecutive years. Our group company Norton Motorcycles, based in the United Kingdom, is one of the most emotive motorcycle brands in the world. Our subsidiaries in the personal e-mobility space, Swiss E-Mobility Group (SEMG) and EGO Movement have a leading position in the e-bike market in Switzerland. TVS Motor Company endeavours to deliver the most superior customer experience across 80 countries in which we operate.For more information, please visit www.tvsmotor.com or write to corpcom@tvsmotor.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Apr 8, 2025 - (ACN Newswire via SeaPRwire.com) - When it comes to symbolising eternal love, nothing captures the essence better than a diamond. ALUXE, Taiwan’s leading diamond and wedding jewellery brand, now brings its legacy of excellence to Singapore, offering an exquisite collection of certified diamonds at competitive prices.Instant Diamond SelectionFinding the perfect diamond has never been easier with ALUXE’s real-time selection of over 30,000 diamonds. Seamlessly integrated with global suppliers, every diamond is displayed with flawless brilliance details and a 360° high-resolution viewing experience. Customers can choose from a wide range of ready-to-go options or secure pre-orders with guaranteed delivery within two months.Competitive Pricing Without CompromiseALUXE eliminates unnecessary mark-ups by sourcing diamonds directly from the world’s top cutters. As one of Taiwan’s largest diamond importers, ALUXE ensures customers receive the highest quality at the best possible price, making premium diamonds more accessible than ever.Certified Excellence for Complete Peace of MindEvery ALUXE diamond comes with internationally recognised certification. Natural diamonds are graded by GIA, the gold standard in diamond evaluation, while lab-grown diamonds are certified by IGI. Additionally, the exclusive ALUXE Ultimate Diamond Report provides advanced scientific analysis of a diamond’s brilliance, ensuring only the finest stones make it to the collection.Fancy Cuts & Rare Colours for Distinctive EleganceBeyond classic round diamonds, ALUXE offers a stunning selection of fancy-cut and rare coloured diamonds, including pink, yellow, and blue hues, allowing customers to express their unique style.ROSÉ My Love – The Pink Diamond CollectionPink diamonds symbolise passion and rarity. ALUXE’s ROSÉ My Love collection features exquisite lab-grown pink diamonds, making this coveted gem more accessible. Ideal for engagements, anniversaries, or meaningful gifts, these diamonds capture the essence of romance.Lovers Collection – The Blue Diamond Wedding RingsBlue diamonds represent purity and everlasting love. The Lovers Collection showcases these rare gems in elegant wedding bands, complemented by platinum settings and inner sapphire accents, offering a timeless symbol of commitment.With decades of expertise, ALUXE is committed to helping couples find the perfect expression of love through meticulously crafted jewellery. Visit ALUXE in Singapore or explore our collection online to discover diamonds that make every love story shine.Discover more at www.aluxe.com/sg-en/About ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/sg-en/ FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/ALUXE LOCATIONSION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6022 1715Opening Hours: 11:00 - 21:30 Copyright 2025 ACN Newswire via SeaPRwire.com.

ATLANTA, GA, Apr 8, 2025 - (ACN Newswire via SeaPRwire.com) - Today marks a pivotal moment in the evolution of global infrastructure as Trading Nations Global officially releases its highly anticipated white paper: Empowering a Quantum-Resilient Future Through Collaboration. This visionary document lays the foundation for a digitally sovereign, quantum-ready world—one powered by decentralized cooperation, green technology, and AI-enabled infrastructure.In an age defined by uncertainty and fragmentation, Trading Nations Global is catalyzing a new era of digital diplomacy and sustainable innovation. Through a robust network of ambassadors spanning 16 global regions, the organization is coordinating the rollout of Regional Centers of Excellence (RCoEs)—localized, sovereign cloud hubs designed to secure data, enable AI, and operate autonomously through renewable energy.“We are not just imagining the future—we are actively building it,” said Earl Q. Davis, founder of Trading Nations Global.“This white paper is a call to unite governments, enterprises, and innovators around a shared infrastructure built for resilience, sovereignty, and sustainability.” said Michael E. Kempton, CEO, Trading Nations Global.Key Insights from the White Paper:Quantum-Resilient Infrastructure: RCoEs are fortified with post-quantum cryptography and tamper-proof digital lineage tracking to future-proof global data flows.Sovereign Cloud Ecosystem: Powered by the Vogon Cloud and the Distributed Quantum Ledger Database (DQLDB), this infrastructure allows for secure, low-latency, and borderless collaboration.Sustainability by Design: Each center is energy-autonomous, running on solar, wind, and hydrogen captured from ambient air—marking a shift toward truly off-grid operations.Partnership-Driven Deployment: Co-selling with Managed Service Providers (MSPs) ensures scalable, regionally tailored implementation with shared revenue models.Community-Led Governance: Infrastructure decisions are made locally, preserving cultural integrity, compliance, and trustImpactful Goals:In the next 12 months: Deploy RCoEs in all 16 regions and onboard over 500 organizations to the Vogon Cloud.By year two: Launch federated AI systems and establish Quantum Digital Asset governance.In the long term: Build a global mesh of quantum-sovereign nodes that power a post-silicon digital economy.This white paper presents not only a roadmap but a rallying point for global actors ready to transcend outdated paradigms. The Trading Nations framework balances high-tech resilience with ethical and equitable design principles—offering a scalable alternative to centralized digital monopoliesJoin the MovementTrading Nations Global is actively welcoming new coalition members—governments, technologists, businesses, and citizens—ready to co-create a secure and sustainable digital future.Read the full white paper and become part of the future today: www.tradingnations.cloud/docs/trading-nations-global-white-paper.pdfAbout Trading Nations GlobalTrading Nations Global is a pioneering global association committed to deploying quantum-resilient, community-led infrastructure that powers secure, interoperable, and sustainable digital economies. With a global footprint and an unwavering commitment to digital sovereignty, Trading Nations Global is building the backbone of tomorrow’s trade and governance. For more information, visit www.tradingnations.cloud/.Media Contact:AmplifiX / PlatodataBryan FeinbergZephyr@platodata.io Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年4月7日 - (亚太商讯 via SeaPRwire.com) - 在经历了1972-1980年、2002年-2012年两轮牛市后，2019年8月1日，美联储十年来首次降息，海外央行纷纷跟进放水，以及国际地缘政治日趋复杂等因素扰动下，美元信用逐渐走弱，作为避险资产的黄金显现独特价值，步入第三轮牛市。持续至今的黄金大牛市下，处于产业链上游的金矿企业无疑是最大受益者之一，不仅表现在产能扩张、业绩增长上，也体现在股价的持续拉升上。港股黄金开采板块中，截至今年3月31日，万国黄金集团（03939.HK）自去年3月以来累计上涨214.46%，近两年的涨幅更超过7倍，领涨整个板块，更远远跑赢大盘。股价能有如此强势表现，得益于万国黄金集团主业转型的成功。同时，公司还于3月10日起进入港股通，流动性获得大幅提升，股价亦再创新高，3月20日盘中创下18.36港元的历史最高点。被纳入港股通标的以来，公司获南下资金持续增持，截至3月底，港股通持股比例增至1.41%，持股市值2.42亿港元。收购金岭矿实现主业转型，迈入高潜力增长新阶段万国黄金集团原名"万国国际矿业"，主要在中国及所罗门群岛从事采矿、矿石选矿及销售精矿产品业务，在2023年之前，一直以旗下新庄矿的精矿产品为主要收入来源，而自2023年之后，金岭矿的收入规模逐渐超过新庄矿，位居第一。出于对黄金走牛趋势的精准预判，万国黄金集团早于2020年4月30日收购了祥符金岭有限公司的77.78%权益，而后者拥有位于所罗门群岛的一处金岭矿90%权益，并于2022年11月起开始试产。整个2023年是金岭矿的产能爆发之年，全年实现收入约人民币6.58亿元，一举超过新庄矿约人民币5.73亿元的总营收，占万国黄金集团总营收的比重提升至50.1%，成为公司第一大收入来源。也正因为金岭矿的产能扩张，使得万国黄金集团2023年业绩大增，收入、归母净利润分别增长93.0%、85.8%。2024年上半年，公司收入、归母净利润继续保持快速增长，增速达59.7%、72.9%，其中金岭矿收入占比进一步提升至约60.5%。看到如此良好势头，公司也趁热打铁，于2024年10月9日完成收购祥符金岭额外20.22%权益，由此拥有祥符金岭的98%权益及金岭矿的88.2%实际权益，将"金岭矿"这一聚宝盆牢牢攥在手中。事实证明，这一策略是极为正确的。随着勘探项目的不断推进及生产工艺的循序改进，金岭矿销量持续提升，使得万国黄金集团的第一大收入来源发生了改变，更名成为水到渠成之事。2024年8月6日起，公司名称正式由原来的"万国国际矿业集团有限公司"更改为"万国黄金集团有限公司"，以全新的企业定位和品牌形象，踏上跨越式发展的快车道。2024年度，核心主营业务升级为黄金开采及销售的万国黄金集团，业绩继续稳步提升。全年实现收入约人民币18.76亿元，同比增加42.6%，其中，来自金岭矿的收入同比增加80.4%，占比63.3%。整体毛利约人民币9.97亿元，同比增加61.0%，整体毛利率53.2%；金岭矿毛利同比增加98.1%，毛利率55.6%，高出整体毛利率2.4个百分点。公司归母净利润约人民币5.75亿元，同比增加71.6%。以上数据可以看出，金岭矿无论是收入、毛利润增幅，还是毛利率，都要高于万国黄金集团的整体水平，对增厚公司盈利产生的引擎作用明显。这也从侧面说明了，公司审时度势，顺应本轮黄金牛市而进行主业转型，经受住了市场的考验。产能爬坡提速进行时，机构看好业务发展前景从投产过程来看，万国黄金集团旗下金岭矿于2022年8月开始堆浸厂试生产，并从2023年1月1日开始浮选厂试生产。于此试产阶段，金岭矿的浮选精矿产量一直在稳步提高，接近其设计产能。根据公司披露，截至2023年12月31日，金岭矿的矿产资源总量为7,200万吨（含金量330万盎司），储量为2,870万吨（含120万盎司黄金）。公司发布的最新数据显示，截至2024年7月31日，金岭矿的矿产资源总量为1.96亿吨（含金量730万盎司），较2023年底增幅分别为172.2%及121.2%。储量为3,070万吨（含130万盎司黄金），较2023年底增加7.0%和8.3%。根据业绩报告，于2024年，金岭矿的采矿量约271.3万吨，同比增加85.0%；选矿量约228.1万吨，同比增加96.9%。对此，民生证券在最新研报中指出，以20年左右的矿山生命周期来预估，未来金岭金矿年产量或能达到10吨以上，成长空间广阔。该行认为，万国黄金集团未来成长空间广阔，随着公司采矿恢复正常，选矿逐步改善，当前产能爬坡预计提速，同时未来还有进一步扩产的可能，叠加金价景气，看好公司后续黄金产量持续增长，迎来量价齐升。中信证券则认为，目前金岭矿项目技改阶段正处于爬坡期，增储落地有望促进项目第二阶段规划和建设，预测金岭矿长期产量潜力有望达到8-10吨/年以上，效益释放正当时，成长前景远大。此外，金岭矿收购的资源对价仅为行业平均水平的三分之一，叠加规模效应以及电力供应改善，成本优势有望进一步夯实。该行预计2025年量增、降本、价涨的延续，将促进万国黄金集团业绩延续快速增长，近期金岭矿资源翻倍式增长为中长期扩产提供支撑，给予公司2015年17倍PE估值，首次覆盖并给予公司"买入"评级，目标价20港元。获纳入恒指及港股通，长期投资价值持续彰显近期，除了2024年度业绩报喜，万国黄金集团还获纳入恒生综合指数，并成为港股通标的，预示着其未来发展将迎来诸多利好。今年2月21日，恒生指数公司公布最新季检结果，其中万国黄金集团满足了包括市值、流动性和上市时间等在内的一系列标准，获纳入恒生综合指数成份股。其后，根据深圳证券交易所公告，因应恒生综合指数成份股定期调整，深港通下的港股通标的证券名单于2025年3月10日起实施重大调整，万国黄金集团获调入，进入港股通名单。被纳入恒指，是资本市场对万国黄金集团长期投资价值的高度认可。恒生指数作为香港市场的重要风向标，其成分股的选择极为严苛，需综合考量公司的市值规模、财务状况、行业地位以及发展前景等多方面因素。公司能够脱颖而出，成为其中一员，充分证明了其在黄金产业领域的稳健实力，以及在业务拓展过程中所展现出的强大竞争力和可持续增长潜力。进入港股通后，万国黄金集团能够显著扩大股东基数，提升公司在国际资本市场的知名度和影响力，进而吸引更多长期稳定的投资者成为公司股东，为公司发展提供坚实的资金保障。同时，有助于吸引更多专业投资者和交易机构参与其股票交易，从而有效改善公司股票的流动性。此外，这也为公司带来了大量的主动和被动配置机会，这些新增的资金配置将为公司发展注入强劲动力。良好的市场表现与资金支持，往往会带来更优的估值待遇。随着万国黄金集团在资本市场的知名度提升、股东基数扩大、流动性增强以及资金配置增加，市场对公司的未来发展预期将进一步提高，使公司享受更高的估值溢价。更高的估值不但意味着公司市值的提升，还将增强公司在融资、并购等方面的优势，为公司实现更大规模的发展和战略布局创造有利条件。多重利好加持，让万国黄金集团站在了牛市的风口之上。在全球货币超发、国际局势多变以及"去美元化"浪潮下，凭借稀缺性和长期储藏性，黄金中长期依旧具备较高的配置价值。通过在黄金产业领域持续深耕，不断创新发展，相信万国黄金集团将以"盈利增长"和"估值提升"双重驱动，为投资者带来超额回报。 Copyright 2025 亚太商讯 via SeaPRwire.com.

Financial Highlights:- In 2024, the total revenue amounted to RMB5,261 million, representing a YoY increase of 25.1% - The revenue of the 4Paradigm Sage AI Platform (the “Sage AI Platform”) business grew by 46.7% YoY to RMB3,676 million, accounting for 69.9% of the total revenue - The SHIFT Intelligent Solutions business recorded revenue of RMB1,022 million, accounting for 19.4% of the total revenue - The revenue of the 4Paradigm SageGPT AIGS Services segment amounted to RMB563 million, accounting for 10.7% of the total revenue- Gross profit was RMB2,245 million, with a gross profit margin of 42.7%- The total R&D expenses reached RMB2,170 million, accounting for 41.2% of revenue- The annual loss attributable to the owners of the Company was RMB269 million, with a reduction of RMB640 million compared to the full year of 2023, narrowing by 70.4% YoY. This marks the fourth consecutive fiscal year of sequential loss reduction since 2021Operation Highlights:- In 2024, the number of lighthouse users served by the Company reached 161, a YoY increase of 16%. The average revenue per lighthouse user was RMB19 million, with a Net Dollar Expansion Rate (NDER) of 110% for lighthouse users in 2024- 4ParadigmSage: During the Reporting Period, the Company launched the vertical world model development and management platform, Sage AI Platform 5.0, and completed multiple minor version upgrades, achieving end-to-end capabilities across the computing layer, platform layer, model layer, and application layer- 4Paradigm SHIFT: During the Reporting Period, the Company launched multiple solutions targeting various application scenarios and continued to update and iterate the functionalities and effectiveness of existing solutions to meet enterprise requirements for accuracy, reliability, and real-time performance in different vertical scenarios- 4Paradigm AIGS: During the Reporting Period, the Company continued to upgrade and optimize the functionality and application performance of products, such as the enterprise software reconfiguration assistant AIGS Builder and the enterprise programming assistant AIGS CodeX, creating an enterprise-level “development assistant” that understands customers, businesses, knowledge and R&D, while enabling fast coding capabilitiesHONG KONG, Apr 1, 2025 - (ACN Newswire via SeaPRwire.com) - A leading enterprise AI software company - Beijing Fourth Paradigm Technology Co., Ltd. (“Fourth Paradigm” or the “Company”, Stock Code: 6682.HK) today announced the consolidated annual results for the year ended December 31, 2024 (the “Reporting Period”).In 2024, Fourth Paradigm achieved strong growth in its overall business. The Company’s total revenue reached RMB5,261 million, representing a YoY increase of 25.1%. Gross profit was RMB2,245 million, with a gross profit margin of 42.7%. The Company highly values technological R&D, and has clear profitability goals. During the Reporting Period, the R&D expenses reached RMB2,170 million, accounting for 41.2% of revenue. The annual loss attributable to the owners of the Company was RMB269 million, with a reduction of RMB640 million compared to the full year of 2023, narrowing by 70.4% YoY. This marks the fourth consecutive fiscal year of sequential loss reduction since 2021.In 2024, Fourth Paradigm committed to creating value for customers, continuously enhancing digital transformation experience for existing customers and increasing user stickiness. During the Reporting Period, the number of lighthouse users served by the Company reached 161, a YoY increase of 16%. The average revenue per lighthouse user was RMB19 million, with a Net Dollar Expansion Rate (NDER) of 110% for lighthouse users in 2024.Benefiting from the surge in AI market demand, the Company’s Sage AI Platform business achieved significant growth, driving steady performance improvement of core business. In March 2024, Fourth Paradigm launched Sage AI Platform 5.0, which integrates vertical world model development and management, enterprise AI agent application suites, GPU resource pooling and other end-to-end capabilities, supporting the large-scale production and application of vertical world models and enterprise AI agents, and continuously driving intelligent transformation and high-quality development across industries.Core business revenue increased by 46.7%, with scaled expansion driving rapid businessAs the core of the Fourth Paradigm’s all businesses, the 4Paradigm Sage AI Platform business achieved significant growth during the Reporting Period, with revenue reaching RMB3,676 million, representing a YoY increase of 46.7% and accounting for 69.9% of total revenue. Scale effects are deepening progressively.In 2024, Fourth Paradigm remained committed to technological innovation, comprehensively enhancing the capabilities of Sage AI Platform. On the basis of end-to-end capabilities across the computing layer, platform layer, model layer, and application layer, Sage AI Platform continued to optimize key capabilities such as AI agent and GPU resource pooling. Among these, AI agent further enhanced its ability to solve complex problems and improve execution accuracy, and developed the enterprise AI agent development platform that covers the entire lifecycle of AI agent design, development, debugging, deployment, operational analysis, and iterative optimization. This empowers enterprise developers to efficiently and scalably build business AI agents with cognitive, decision-making, and execution capabilities – all on demand. As a result, development cycles have been reduced by over 95% in most cases. The GPU resource pooling capability enables enterprises to achieve platform-level management of hardware clusters, on-demand allocation of computing resources, and rapid scheduling, helping to address challenges such as low utilization of heterogeneous computing resources and high costs of adapting large models to computing power. According to the latest report from the internationally authoritative research firm IDC, Fourth Paradigm has maintained its position as the leader in China’s machine learning platform market share for six consecutive years.While scaling its core business, Fourth Paradigm has also made steady progress in its two other major businesses – SHIFT Intelligent Solutions business and 4Paradigm AIGS service business, which provide strong support for the core business – Sage AI Platform, driving efficient growth across the overall business.During the Reporting Period, revenue from SHIFT Intelligent Solutions totaled RMB1,022 million, comprising 19.4% of the total revenue. This business is built on the Sage AI Platform, tailored to different industry business scenarios. These solutions enable Fourth Paradigm’s technology and capabilities to penetrate a wider range of industries and scenarios, addressing critical business challenges for traditional enterprises and driving digital and intelligent transformation across industries. Due to the impact of the business expansion strategy, the revenue from this business decreased by 20.3% YoY while the revenue from Sage AI Platform business achieved 46.7% YoY growth.In addition, the revenue from the 4Paradigm SageGPT AIGS Services business during the Reporting Period reached RMB563 million, accounting for 10.7% of the Company’s total revenue. This business provides efficient development tools and services based on generative AI for the Sage AI Platform business, enabling multi-fold increases in enterprise R&D productivity.“AI agent + Vertical World Model” dual-core architecture builds the AGI foundation, enabling continuous expansion of the business ecosystemIn recent years, the continuous advancement of generative AI technologies has accelerated progress toward Artificial General Intelligence (AGI), a consensus widely recognized across the industry. As an enterprise with over a decade of experience in the AI sector, Fourth Paradigm is committed to empowering industries through its core philosophy of “AI agent + Vertical World Model”, which uses AI agents to understand human needs and leveraging corresponding vertical world models to solve problems, while continuously enhancing their respective capabilities – will ultimately drive the realization of AGI.Over the past year, adhering to the philosophy of “AI agent + Vertical World Model”, Fourth Paradigm has collaborated with numerous industry partners and has successfully implemented hundreds of reliable and controllable enterprise-level AI agent applications, covering scenarios such as financial credit risk control, water and electricity equipment maintenance, hydrological data monitoring, chronic disease management, intelligent course learning, automotive manufacturing MES system management, fluid dynamics design, intelligent after-sales customer service and academic administration assistant, comprehensively driving the intelligent transformation for enterprises.At the same time, Fourth Paradigm, in collaboration with partners, has released several out-of-the-box user-level agent solutions, such as intelligent meeting solutions, intelligent mouse solutions, and desktop AI search tools. These solutions cover AI agent capabilities such as simultaneous interpretation, one-click translation, robotic assistants, AI writing, and intelligent cross-platform search, helping enterprise business personnel achieve a leap in daily work efficiency.In addition, since the advent of DeepSeek, the inference and deployment costs of large models have significantly decreased, catalyzing market demand across large model implementation, integrated solutions deployment, and on-device AI applications. Fourth Paradigm has rapidly iterated its technical capabilities and product adaptations to deliver high-value solutions addressing these market needs.In terms of integrated solutions, Fourth Paradigm launched the out-of-the-box SageOne IA large model inference integrated solution, which enables seamless switching between the full-capacity model and multiple distilled models while supporting mainstream large models. This increases GPU utilization by over 30% and improves inference performance by an average of 5-10 times. Furthermore, SageOne IA comes with a rich suite of AI applications, helping developers efficiently create enterprise-level generative AI applications.For on-device AI, Fourth Paradigm launched the ModelHub AIoT on-device inference solution. This solution allows users to easily deploy small-sized distilled models such as DeepSeek R1, Qwen 2.5, and Llama 2/3 series on on-device devices for offline operation. It also balances model compression and inference performance while addressing the complexities of deployment and optimization. In addition, the Company has further expanded these capabilities into the consumer electronics sector, delivering AI Agent solutions that integrate hardware and software. That empowers consumer electronics manufacturers to launch AI-enabled terminal products that resonate with their users.In terms of Strategic Outlooks, Dr. Dai Wenyuan, Chairman of the Board, Executive Director, Chief Executive Officer and General Manager of Beijing Fourth Paradigm Technology Co., Ltd. said, “In recent years, generative AI has gained widespread recognition globally. As an AI technology service provider with over a decade of experience in the enterprise service sector, we have a deeper and more accurate understanding of how to organically integrate these rapidly evolving AI technologies to empower our enterprise clients, create tangible business value, and deliver practical efficiency improvements for both enterprises and individuals. This aligns with our ultimate vision that has always guided our business – AI for Everyone. Looking ahead, we will build on our decade-long expertise in the enterprise service sector, look toward the broader AI market, and leverage our AI capabilities to transform all possible business domains. We believe that the convergence of these diverse capabilities will form the cornerstone for achieving AGI.” Copyright 2025 ACN Newswire via SeaPRwire.com.

Marrakech, Morocco, Apr 8, 2025 - (ACN Newswire via SeaPRwire.com) - Morocco WEB3FEST GITEX Edition, a global conference series focused on technology and innovation in AI, Blockchain, and sustainability, organized by InactaVentures and co-hosted by The Hashgraph Association, being carried out in Marrakech, Morocco from April 14-16, 2025 is set to bring together the world’s foremost Web3 leaders, innovators, and investors at the intersection of technology, finance, and sustainability. Hosted in Marrakech during GITEX Africa, this premier event serves as a critical bridge linking the vibrant ecosystems of Africa, the Middle East, and Europe.With a strong commitment to advancingdecentralized technologies and sustainable innovation, Morocco WEB3FEST GITEX Edition is poised to drive meaningful dialogue and collaboration among industry pioneers, enterprises, and policymakers.What is the WEB3FEST?WEB3FEST is a global conference series focused on technology and innovation in AI, Blockchain and Sustainability. It serves as a vibrant hub where companies across the value chain – from agile startups to international corporations – converge to share ideas, build networks, and shape the future of the industry.Kamal Youssefi - President of The Hashgraph Association noted, “We are honored to be co- hosting the WEB3FEST in Morocco during GITEX Africa given that one of the aims of THA is to empower entrepreneurs, enterprises and governments with the technologies and knowhow needed to foray into Web3 while keepingsustainability at the heart of their endeavors. This is why Hedera network, considered one of the most sustainable in the world, is at the center of our conversations.”Ralf Glabischnig – Founder of Inacta Ventures, added, "Switzerland has always been a hub for Blockchaininnovation, and our Layer 1 technology is solving real-world challenges in developing countries. With Morocco as the perfect gateway to Africa, we are connecting European expertise with Africa’s immense potential for Blockchain adoption."Event Highlights:The Green Block TalksApril 14, 2025Sofitel Marrakech Palais ImperialA high-impact evening bringing together thought leaders and industry experts to discuss the role of AI and Web3 in driving sustainability. Featuring insightful panels, networking opportunities, and meaningful discussions.Featured Speakers:Ian Putter – Head of Blockchain COE, Standard BankTom Rieder – Director Marketplace, The Green BlockAbdelaziz Benyahya – Chief Transformation Officer, AXA MoroccoKamal Youssefi – President of The Board, The Hashgraph AssociationRalf Glabischnig – Founder, Inacta VenturesWEB3 Investor Dinner (Co-hosted by NEO AI)April 15, 2025Private Villa, MarrakechAn exclusive, invitation-only gathering for venture capitalists, fund managers, and private equity professionals.This intimate setting will facilitate high-level discussions on investment opportunities, portfolio strategies, and the evolving digital asset landscape.About the Organizer Inacta VenturesAt the helm of the WEB3 revolution, Inacta Ventures builds ecosystems, ventures, and smart capital strategies.With operations in the thriving Crypto Valley in Switzerland and the Crypto Oasis in the UAE, Inacta empowers over 100 portfolio companies and enterprises to scale groundbreaking WEB3 solutions.About the Co-Host The Hashgraph AssociationThe Hashgraph Association, a Swiss non-profit, drives global adoption of Hedera-powered solutions by funding innovation, training, and venture programs. It promotes economic inclusion and a digital future with a positive ESG impact. https://www.hashgraph.swiss/aboutRegistrationReserve your spot now and join the world’s brightest minds to shape the future of WEB3: Register HereFor more details, visit: web3fest.chContact:Fabio SchlafHead of Ecosystem Development Inacta Ventures & Crypto Oasis fabio.schlaf@inactaventures.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 3, 2025 - (ACN Newswire via SeaPRwire.com) - JBM (Healthcare) Limited (“JBM Healthcare”; Stock Code: 2161, together with its subsidiaries, the “Group”), a leading branded healthcare products marketer and distributor in Hong Kong, announced today that it has acquired a 90% stake in Tin Hee Tong Medicine Factory, Limited (“Tin Hee Tong”,), at a total consideration of HK$171.0 million. Tin Hee Tong has now become a non-wholly owned subsidiary of JBM Healthcare.Strengthening the Portfolio with a Trusted Heritage BrandTin Hee Tong’s flagship product, Tin Hee Tong Tin Hee Pills, has a rich legacy and strong brand recognition across Hong Kong and Mainland China, particularly in Guangdong Province. The product is well formulated for regulating the female menstrual cycle, promoting reproductive health, and enhancing blood circulation for a radiant complexion. Tin Hee Tong Tin Hee Pills is a highly trusted brand for gynecological well-being among female consumers. Recognising its distinctive market position and long-term growth potential, the Group sees this acquisition as a valuable strategic fit for its proprietary Chinese medicines portfolio.Unlocking Growth Potential & SynergiesThe acquisition presents a compelling opportunity to expand the Group’s portfolio of proprietary Chinese medicines and accelerate its growth strategy. By integrating this iconic brand into its existing lineup, the Group is well-positioned to capitalise on rising consumer demand for holistic healthcare solutions.To maximise the brand’s potential, the Group plans to launch a comprehensive marketing campaign, leveraging its extensive expertise in brand management and revitalisation to boost consumer awareness and engagement. Additionally, the Group will expand distribution networks to capitalise on new market opportunities and customer segments. By combining the complementary strengths of both businesses, the acquisition is expected to generate significant synergies, reinforcing the Group’s strategy of acquiring assets that align with its long-term vision and create shareholders’ value.Proven Track Record in Brand RevitalisationThe Group has a proven track record of revitalising heritage proprietary medicines brands, effectively transforming legacy products into prominent market players. Its portfolio includes iconic brands such as Po Chai Pills — a market leader in proprietary Chinese gastrointestinal medicines, Ho Chai Kung — a widely recognised household name in the OTC pain killer category, and Flying Eagle Woodlok Oil — a rejuvenated brand in the traditional Chinese medicated oil sector, driven by creative advertising that blends Hong Kong nostalgia with broad consumer appeal.Through strategic brand revitalisation, omni-channel expansion, and digitally driven consumer engagement strategies, the Group has successfully transformed heritage brands into contemporary wellness solutions that resonate with both loyal customers and the younger, generations. With Tin Hee Tong Tin Hee Pills, JBM Healthcare is set to reinvigorate this trusted brand and expand its market presence.Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare said, “The acquisition of Tin Hee Tong represents a pivotal step in strengthening our leadership in the proprietary Chinese medicines sector. With its rich heritage and strong recognition, Tin Hee Tong Tin Hee Pills is a highly complementary addition to our portfolio. Drawing on our proven brand revitalisation expertise, we are confident in unlocking its full growth potential and delivering long-term value to our shareholders.”About JBM (Healthcare) Limited; Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills , Ho Chai Kung Tji Thung San , Tin Hee Tong Tin Hee Pills , Flying Eagle Woodlok Oil , Tong Tai Chung Woodlok Oil , Shiling Oil , Konsodona Medicated Oil , Contractubex and Mederma for Kids . JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Mar 31, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2024 (the "Reporting Period"). During the year, the Group adhered to its overall business philosophy of “in-depth services and lean operations”, promoted development with innovation, deepened integrated collaboration among “government, industry, academy, research, medicine, application”, accelerated digital application of “AI + medical care”, continuously strengthened refined management, and reduced cost and improved efficiency, demonstrating strong operational resilience.In 2024, due to changes in the macro-environment, intensified competition in the industry as well as its strategic decision to optimize customer structure and product mix, the Group’s performance was temporarily affected. However, relying on its customer-oriented, innovative and coordinated development system, the Group achieved many breakthroughs in product innovation, model innovation, AI + medical digital intelligence and other aspects. The joint construction business with medical institution alliances remained its largest business segment, which accounted for 53.0% of the total revenue, representing an increase of 4.7 percentage points as compared to the same period of the previous year. In addition, featured products in the infection segment achieved rapid growth, laying a solid foundation for the segment’s long-term development. During the Reporting Period, the Group’s total revenue reached RMB711.9 million.Diagnostic testing for medical institution alliances was developing healthily In-depth service empowers customersYunkang is committed to developing an innovative service mode for joint construction of medical institution alliances with “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. At present, the Group is providing medical technical service solutions to over 1,500 medical institutions in collaboration with medical institution alliances at over 430 on-site diagnostic centers of the alliances to meet their core demands. Through close collaboration – mutual recognition of testing results – with leading regional medical institutions, the Group has helped improve overall regional medical and treatment levels, helping hospitals build specialty departments, improving the efficiency of hierarchical diagnosis and treatment, promoting scientific research and cooperation, etc., thereby providing the public with higher-quality and more efficient diagnosis and treatment services. Dedicated to vigorously driving medical reform in China, during the Reporting Period, Yunkang teamed up with leading provincial-level hospitals, and regional county-level general hospitals to jointly build medical institution alliances to actively promote the construction of medical institution alliances as the bridge that connects the regional testing centers and partner hospitals. Customers are provided with “3+N” tumor, infection, reproductive genetics and +N technical system support, and also support from the in-depth service system, including the operation of diagnostic centers under regional medical institution alliances, access to new technologies or new products, construction services for digital specialty departments, medical cold chain logistics services, quality control services and supply chain services, all in-depth services for empowering demand and the long-term development of hospitals.Focus on “clinical demands” Joint innovation for diagnostic testing achieved remarkable resultsAdhering to the “clinical demands”-oriented service concept, the Group has built a series of high-tech platforms, including high-throughput sequencing, gene chip, high-sensitivity PCR, protein spectrometry, cytogenetics, digital remote pathology, and ultra-micro pathology. During the Reporting Period, the Group introduced nearly 800 new testing items and provided about 3,800 clinical testing items, and more than 10 million specimens were tested for the year. In terms of precision diagnosis and treatment, the Group carried out more than 500 precision diagnosis services using cutting-edge technologies such as high-throughput sequencing, and protein spectrometry, covering five medical fields including infectious diseases, reproductive genetics, solid tumors, blood diseases, and personalized medicine. During the Reporting Period, the Group focused on the construction and development of 58 new items in such fields including infection, tumor, rare genetic diseases and personalized medicine, providing medical institutions nationwide with a more comprehensive range of precision diagnosis solutions to drive the embrace and development of precision medicine. During the Reporting Period, revenue from special testing items increased significantly year-on-year, accounting for a larger percentage of the Group’s overall revenue.The Group has a first-of-its-kind “joint innovation platform for diagnostic testing”, which has played a vital role in expanding its business and boosting competitiveness of its products. Constantly exploring and putting ideas into practice, the Group and dozens of top medical institutions across the country have pursued joint innovation for diagnostic testing and successfully developed more than 10 testing products for different infection syndromes in various fields such as respiratory tract infections and central nervous system infections.Digital application of “AI + medical care” leads the industryThe Group has launched and continuously upgraded its top 10 digital “cloud” systems, covering core areas such as laboratory operations, sales management, human resources, staff training, and customer services. At the same time, it has integrated AI technology into its “cloud” systems to create a one-stop intelligent medical diagnostic solution covering from “sample collection” to “report delivery”, which was comprehensively applied across its multi-technology platforms in medical laboratories, with the core concepts of “Internet+” and “precision diagnosis” to create a series of intelligent diagnostic platforms. In the Reporting Period, the Group’s self-developed digital IT platform with full intellectual property rights – the remote pathology consultation platform – covered over 800 medical testing items, assisting nearly 300 medical institutions nationwide in enhancing their pathology diagnostic capabilities and benefiting more than 200 million patients in rural areas.Regarding the application of AI-assisted diagnosis, the Group adheres to the strategy of “introducing one item once it is mature” and closely follows industry development trends. It has introduced items such as pathological DNA polyploid AI-assisted diagnosis, cervical liquid-based cell AI-assisted diagnosis, and chromosome AI analysis, all proven effective and have greatly enhanced diagnostic efficiency. During the Reporting Period, the Group focused on the field of infectious diseases and developed its first infectious disease data product, the “Yunkang Respiratory Pathogen Detection Positivity Rate Analysis Report”. The product officially obtained data product certification and was listed on the Guangzhou Data Exchange in January 2025, marking a milestone step for the Group in the field of compliant data transactions, effectively unlocking data value. Currently, having access to the DeepSeek large model, the Group aims to achieve comprehensive innovation in medical testing and diagnostics through inclusive technology, precision service and intelligent management.Collaborative and integrated development of “government, industry, academy, research, medicine, application” to facilitate industrial upgradeDuring the Year, the Group collaborated with various institutions to facilitate industrial upgrade based on a unique innovative industrial model, including:- Collaboration with The People’s Government of Ouhai, Wenzhou City and Wenzhou Medical University’s core areas in biomedical industry to promote construction of a number of key projects including a joint innovation and transformation platform, a public service platform, a medical big data research platform, a regional diagnostic sharing center and a training base for innovative talent, to the end of facilitating quick transformation of scientific research results for industrial applications;- Collaboration with The Zhangjiang Research Institute of Fudan University to jointly establish a “Collaborative Innovation and Transformation Center” to promote innovation and transformation of results of medical diagnostic technology application;- Collaboration with The Central University of Finance and Economics, Greater Bay Area Research Institute to jointly build an industry-education fusion talent cultivation highland and an industry aggregation and incubation platform.The strategy for sustainable development drives long-term valueWhile vigorously driving business development, Yunkang has consistently viewed sustainable development as a core strategy of the Group, committed to promoting the green transformation of the healthcare industry through innovative technologies and in-depth services. The Group engaged in environmental protection efforts such as energy conservation, emission reduction, and resource recycling in its operations, while also launched various charitable initiatives, including charitable clinical diagnostic activities, health checkup services for the well-being of the community, and health seminars, to give back to society by making use of its professional advantages. Looking ahead, Yunkang will continue to make progress in ESG and step up our efforts in such areas as environmental policy and management, Scope 3 emissions, climate governance, climate performance indicators, climate scenario analysis, carbon reduction targets, and net-zero emissions commitment, all of which will help us realize economic, environmental and social benefits.Future prospectsChina has continued to promote expansion and downward penetration of the country’s high-quality medical resources, fostering a balanced regional layout and stepping up the construction of a hierarchical diagnosis and treatment system, conducive to establishing close-knit medical institution alliances. China’s Laboratory Developed Testing methods (LDT) pilots have steady and notable progress, leading to market growth for precision medicine development. In addition, in-depth integration of AI technology with the healthcare industry will become an important driving force for fine industry segments to embark on digital intelligence transformation and upgrade. Looking ahead, Yunkang will continue to align with national policies, seize the latest industry development opportunities, and continue to strengthen clinical-empowered value, and constantly explore and deepen the two new “product innovation + model innovation” model with customers in mind and to ensure residents can better benefit from its medical achievements.Yunkang Group Limited（Stock Code：2325）Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to 430+ on-site diagnostic centers. As of December 31, 2024, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com.